Literature DB >> 430598

Inhibition of coronavirus 229E replication by actinomycin D.

D A Kennedy, C M Johnson-Lussenburg.   

Abstract

The yields of human coronavirus 229E grown in L132 cells were markedly inhibited by actinomycin D, the 50% inhibitory dose being 0.1 micron/ml. Inhibition was maximal during the early phase of virus replication, did not appear to involve viral RNA synthesis per se, and was shown to be dependent on the input multiplicity of infection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 430598      PMCID: PMC353142     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  11 in total

1.  OBSERVATIONS ON THE GROWTH OF MOUSE HEPATITIS VIRUS (MHV-3) IN MOUSE MACROPHAGES.

Authors:  L MALLUCCI
Journal:  Virology       Date:  1965-01       Impact factor: 3.616

2.  RNA of mouse hepatitis virus.

Authors:  M M Lai; S A Stohlman
Journal:  J Virol       Date:  1978-05       Impact factor: 5.103

3.  The effect of 5-bromodoxyuridine and actinomycin D on the multiplication of transmissible gastroenteritis virus.

Authors:  M C Clarke
Journal:  J Gen Virol       Date:  1968-09       Impact factor: 3.891

4.  Ribonucleic acid synthesis in porcine cell cultures infected with transmissible gastroenteritis virus.

Authors:  N K Mishra; W L Ryan
Journal:  Am J Vet Res       Date:  1973-02       Impact factor: 1.156

5.  Biological properties of avian coronavirus RNA.

Authors:  B Lomniczi
Journal:  J Gen Virol       Date:  1977-09       Impact factor: 3.891

6.  Presence of genomic polyadenylate and absence of detectable virion transcriptase in human coronavirus OC-43.

Authors:  G A Tannock; J C Hierholzer
Journal:  J Gen Virol       Date:  1978-04       Impact factor: 3.891

7.  The characterisation of the virion RNA of avian infectious bronchitis virus.

Authors:  M R Macnaughton; M H Madge
Journal:  FEBS Lett       Date:  1977-05-15       Impact factor: 4.124

8.  Rat coronavirus (RCV): a prevalent, naturally occurring pneumotropic virus of rats.

Authors:  J C Parker; S S Cross; W P Rowe
Journal:  Arch Gesamte Virusforsch       Date:  1970

9.  Presence of infectious polyadenylated RNA in coronavirus avian bronchitis virus.

Authors:  G Schochetman; R H Stevens; R W Simpson
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

View more
  9 in total

Review 1.  The molecular biology of coronaviruses.

Authors:  Paul S Masters
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

2.  Coronavirus multiplication strategy. I. Identification and characterization of virus-specified RNA.

Authors:  D F Stern; S I Kennedy
Journal:  J Virol       Date:  1980-06       Impact factor: 5.103

3.  The replication of murine coronaviruses in enucleated cells.

Authors:  K C Wilhelmsen; J L Leibowitz; C W Bond; J A Robb
Journal:  Virology       Date:  1981-04-15       Impact factor: 3.616

Review 4.  The pathogenesis of Rift Valley fever.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Viruses       Date:  2011-05       Impact factor: 5.048

Review 5.  The molecular biology of coronaviruses.

Authors:  M M Lai; D Cavanagh
Journal:  Adv Virus Res       Date:  1997       Impact factor: 9.937

Review 6.  Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.

Authors:  Seyed Abdulmajid Ayatollahi; Javad Sharifi-Rad; Patrick Valere Tsouh Fokou; Gail B Mahady; Hafiz Ansar Rasul Suleria; Shivani Krishna Kapuganti; Kundlik Gadhave; Rajanish Giri; Neha Garg; Rohit Sharma; Daniel Ribeiro; Célia F Rodrigues; Željko Reiner; Yasaman Taheri; Natália Cruz-Martins
Journal:  Front Pharmacol       Date:  2021-06-29       Impact factor: 5.810

7.  The coronavirus avian infectious bronchitis virus requires the cell nucleus and host transcriptional factors.

Authors:  M R Evans; R W Simpson
Journal:  Virology       Date:  1980-09       Impact factor: 3.616

8.  Replication and morphogenesis of avian coronavirus in Vero cells and their inhibition by monensin.

Authors:  F V Alonso-Caplen; Y Matsuoka; G E Wilcox; R W Compans
Journal:  Virus Res       Date:  1984       Impact factor: 3.303

Review 9.  Repurposing anticancer drugs for the management of COVID-19.

Authors:  Khalid El Bairi; Dario Trapani; Angelica Petrillo; Cécile Le Page; Hanaa Zbakh; Bruno Daniele; Rhizlane Belbaraka; Giuseppe Curigliano; Said Afqir
Journal:  Eur J Cancer       Date:  2020-09-22       Impact factor: 9.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.